NCT07204327View on ClinicalTrials.gov

Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)

Active, not recruitingOBSERVATIONAL
Enrollment

1,136

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
OTHER

Atezo+Bev plus Locoregional Therapy

Patients received atezolizumab plus bevacizumab (Atezo+Bev) in combination with at least one locoregional therapy (transarterial chemoembolization \[TACE\], hepatic arterial infusion chemotherapy \[HAIC\], transarterial radioembolization \[TARE\], ablation, or radiotherapy) within ±2 months of systemic therapy initiation, in routine clinical practice.

Trial Locations (1)

210009

Zhongda Hospital, Southeast University, Nanjing

All Listed Sponsors
lead

Zhongda Hospital

OTHER